Common Contracts

GALECTIN THERAPEUTICS INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement

Galectin Therapeutics Inc • May 19th, 2017 • Pharmaceutical preparations • New York

• Company
  Galectin Therapeutics Inc
• Filed
  May 19th, 2017
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Galectin Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), as follows:

PSIVIDA CORP. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement

pSivida Corp. • February 8th, 2017 • Laboratory analytical instruments • New York

• Company
  pSivida Corp.
• Filed
  February 8th, 2017
• Industry
  Laboratory analytical instruments
• Jurisdiction
  New York

pSivida Corp., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), as follows:

EVOKE PHARMA, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement

Evoke Pharma Inc • April 15th, 2016 • Pharmaceutical preparations • New York

• Company
  Evoke Pharma Inc
• Filed
  April 15th, 2016
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Evoke Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”), as follows:

NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement

NephroGenex, Inc. • August 7th, 2015 • Pharmaceutical preparations • New York

• Company
  NephroGenex, Inc.
• Filed
  August 7th, 2015
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

NephroGenex, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement

NephroGenex, Inc. • August 7th, 2015 • Pharmaceutical preparations • New York

• Company
  NephroGenex, Inc.
• Filed
  August 7th, 2015
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

NephroGenex, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

AVEO PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement

Aveo Pharmaceuticals Inc • February 27th, 2015 • Pharmaceutical preparations • New York

• Company
  Aveo Pharmaceuticals Inc
• Filed
  February 27th, 2015
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Aveo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:

EVOKE PHARMA, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement

Evoke Pharma Inc • November 13th, 2014 • Pharmaceutical preparations • New York

• Company
  Evoke Pharma Inc
• Filed
  November 13th, 2014
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Evoke Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

SORRENTO THERAPEUTICS, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement

Sorrento Therapeutics, Inc. • November 4th, 2014 • Services-commercial physical & biological research • New York

• Company
  Sorrento Therapeutics, Inc.
• Filed
  November 4th, 2014
• Industry
  Services-commercial physical & biological research
• Jurisdiction
  New York

Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:

CONATUS PHARMACEUTICALS INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement

Conatus Pharmaceuticals Inc. • August 14th, 2014 • Pharmaceutical preparations • New York

• Company
  Conatus Pharmaceuticals Inc.
• Filed
  August 14th, 2014
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Conatus Pharmaceuticals Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

CORONADO BIOSCIENCES, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement

Coronado Biosciences Inc • October 5th, 2012 • Pharmaceutical preparations • New York

• Company
  Coronado Biosciences Inc
• Filed
  October 5th, 2012
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Coronado Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows: